Table.
Baseline Characteristics of the Cohort of 64 Hepatitis C Virus (HCV)-Infected Homeless and Marginally Housed Adults Treated With Oral Therapy
| Characteristic | Sustained Virologic Response, No. (%) | |
|---|---|---|
| Not Achieved (n = 2) | Achieved (n = 62) | |
| Age, mean (SD), y | 53.5 (7.8) | 55.5 (7.7) |
| Sex | ||
| Male | 1 (50) | 48 (77) |
| Race | ||
| Nonwhite | 1 (50) | 28 (53) |
| Ethnicity | ||
| Hispanic | 0 | 45 (74) |
| Veteran | 0 | 5 (8) |
| Education | ||
| <High school graduate orGED | 1 (50) | 25 (42) |
| Employment | ||
| Part-time | 2 (100) | 7 (12) |
| Full-time | 0 | 6 (10) |
| Unemployed | 0 | 20 (33) |
| Disability | 0 | 27 (45) |
| Insured | 2 (100) | 60 (97) |
| History of incarceration | 0 | 22 (36) |
| Homeless | 0 | 26 (42) |
| HIV coinfected | 0 | 29 (47) |
| Genotype | ||
| Mixed | 0 | 7 (11) |
| 1 | 1 (50) | 49 (79) |
| 2 | 1 (50) | 3 (5) |
| 4 | 0 | 3 (5) |
| Fibrosis-4 value, mean (SD) | 4.34 | 3.80 (5.84) |
| METAVIR stage | ||
| F0 | 0 | 3 (5) |
| F1 | 0 | 22 (36) |
| F2 | 0 | 9 (14) |
| F3 | 0 | 6 (10) |
| F4 | 2 (100) | 22 (35) |
| Reactive | ||
| Hepatitis Avirus | 1 (100) | 48 (83) |
| Hepatitis B virus | 0 | 29 (49) |
| Alanine aminotransferase level, U/L, mean (SD) | 98.5 (50.5) | 63.5 (6.1) |
| HCV treatment experience | 0 | 12 (19) |
| HCV treatment regimen | ||
| Sofosbuvir-ribavirin | 1 (50) | 3 (5) |
| Simeprevir-sofosbuvir | 0 | 5 (8) |
| Ledipasvir-sofosbuvir | 1 (50) | 49 (79) |
| Ledipasvir-sofosbuvir-ribavirin | 0 | 5 (8) |
| History of IDU | 1 (50) | 46 (84) |
| Used drugs (including marijuana) during HCVtreatment | 0 | 16 (26) |
Abbreviations: GED, General Educational Development test; HIV, human immunodeficiency virus; IDU, injection drug use.
SI conversion factor: To convert alanine aminotransferase to microkatals per liter, multiply by 0.0167.